Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study

Clinical Oncology

Volumn 15, Issue 6, 2003, Pages 318-321

  Henderson, A ^a   Langley, S E M ^a   Laing, Robert W ^b  

^a St Lukes's Cancer Centre   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Anti androgens; Bicalutamide; Brachytherapy; Goserelin; Hormone; LHRH analogues; Prostate cancer; Prostate volume

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; GOSERELIN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING;

EID: 0042140586     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(03)00093-1     Document Type: Article

References (20)

1. Whittington R, Broderick GA, Arger P. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44:1107-1110.
2. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150:359-364.
3. Shearer RJ, Davies JH, Gelister JS. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69:521-524.
4. Rousseau L, Dupont A, Labrie F. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav 1988;17:87-98.
5. Austoni E, Colombo F, Mantovani F. Andrologic problems in prostatic carcinoma. Arch Ital Urol Androl 1993;65:517-522.
6. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999;6:19-23.
7. See WA, Wirth MP, McLeod DG. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-435.
8. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 1993;150:90-94.
9. Wirth M, Tyrrell C, Wallace M. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001;58:146-151.
10. Tyrrell CJ, Kaisary AV, Iversen P. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-456.
11. Pilepich MV, Winter K, John MJ. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.
12. Hanks GE, Lu J, Machtay M. RTOG Protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000; 19:1284.
13. Messing EM, Manola J, Sarosdy M. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-1788.
14. Zietman AL, Nakfoor BM, Prince EA. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997; 3:31-36.
15. Pilepich MV, Krall JM, Sause WT. Prognostic factors in carcinoma of the prostate - analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987;13:339-349.
16. Lu T, Macaret M, Nelson J. The barrel shaped cervix. Am J Obstet Gynaecol 1976;124:596-600.
17. Movsas B, Chapman JD, Hanlon AL. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol 2001; 24:458-461.
18. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997;49:38-45.
19. Stone NN, Stock RG, Unger P. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. Mol Urol 2000;4:163-168 discussion; 169-170.
20. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444-452.